-
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
-
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
-
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
-
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media Release
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media Release
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media Release
Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS